This study provides a novel non-BCMA-targeted strategy for advanced treatment of multiple myeloma, particularly beneficial for patients progressing after BCMA-directed therapies, suggesting that rational sequential application of T-cell redirecting therapies may improve clinical outcomes.
Literature Overview
This article, 'FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial,' published in Nature Medicine, systematically investigates the safety, tolerability, and antitumor activity of cevostamab, a bispecific antibody targeting FcRH5, in patients with advanced multiple myeloma. The study employs a dose-escalation and expansion design to evaluate the efficacy of fixed-duration treatment, with particular attention to management strategies for cytokine release syndrome (CRS). This research fills a critical clinical gap in the absence of effective interventions following failure of BCMA-targeted therapies.Background Knowledge
Multiple myeloma (MM) is an incurable plasma cell malignancy, and nearly all patients eventually develop triple-class resistance (to anti-CD38, proteasome inhibitors, and immunomodulatory drugs), termed triple-refractory multiple myeloma. Although BCMA-targeted CAR-T and bispecific antibodies have significantly improved outcomes, most patients still relapse, and some experience antigen escape or T-cell exhaustion. Moreover, while GPRC5D-targeted therapies are effective, they are associated with on-target, off-tumor toxicities such as skin and nail disorders. Therefore, developing T-cell redirecting therapies targeting non-BCMA antigens is an urgent unmet need.
FcRH5 (Fc receptor homolog protein 5) is a B-cell lineage-specific membrane protein widely expressed on nearly all multiple myeloma cells, with no significant correlation to BCMA expression, making it an ideal alternative target. However, the endogenous function of FcRH5 is not fully understood, and its expression on normal B cells may pose potential toxicity risks. This study, driven by this unmet clinical need and target potential, developed cevostamab, the first-generation humanized IgG1 FcRH5×CD3 bispecific antibody, designed to eliminate myeloma cells via T-cell-mediated cytotoxicity.
Research Methods and Experiments
The study adopted an open-label, multicenter phase 1 design (GO39775, NCT03275103), enrolling 324 patients with advanced multiple myeloma, who had received a median of six prior lines of therapy, with 89.5% being triple-refractory and 47.5% having previously received BCMA-targeted therapy. Patients received step-up dosing to reduce CRS risk, followed by intravenous infusions every three weeks at the target dose (TD) for up to 17 cycles (approximately 12 months). Primary endpoints were safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D). Key design elements included various step-up regimens (single/double/triple step) and TD ranges (0.15–252 mg), with optimal dose combinations determined through exposure-response analysis.
For mechanistic validation, the study confirmed widespread FcRH5 expression in tumor samples via flow cytometry and assessed the incidence of anti-drug antibodies (ADA) and neutralizing antibodies. Pharmacokinetic analysis showed dose-proportional systemic exposure with a half-life of approximately 13 days. Additionally, the study evaluated minimal residual disease (MRD) negativity rates and explored the relationship between FcRH5 expression levels and efficacy in biomarker-evaluable patients.Key Conclusions and Perspectives
Research Significance and Prospects
This study establishes FcRH5 as a viable target in multiple myeloma therapy, advancing the clinical development of non-BCMA-targeted bispecific antibodies. Its fixed-duration treatment design may reduce long-term T-cell exhaustion and infection risk, complementing continuous treatment strategies. Future studies should explore the use of cevostamab in earlier lines of therapy and its potential combinations with standard regimens (e.g., pomalidomide).
From a clinical monitoring perspective, standardized assessment protocols for CRS and neurotoxicity are needed, along with exploration of predictive biomarkers such as T-cell phenotypes and cytokine profiles to optimize patient management. Additionally, long-term follow-up data will reveal the durability of responses and potential late-onset toxicities.
Conclusion
This study marks a significant step toward the era of non-BCMA-targeted therapy in multiple myeloma. Cevostamab demonstrates manageable safety and notable antitumor activity in heavily pretreated patients, with particularly strong efficacy in BCMA-naïve individuals. Its fixed-duration treatment design may reduce infection burden associated with prolonged immunosuppression, improving quality of life. From bench to bedside, this study not only validates the therapeutic potential of FcRH5 but also provides evidence supporting the rational sequential use of T-cell redirecting therapies. In the future, integrating MRD-guided personalized treatment strategies may further extend response durations and advance the management of multiple myeloma toward a chronic disease model. Furthermore, the success of FcRH5-targeted therapy will inspire exploration of additional alternative targets, enriching the arsenal of T-cell immunotherapies and ultimately improving patient survival and quality of life.
